HER2 Support Group Forums - View Single Post - 3000 person study-- her2+ early breast cancer divided into two groups by HR status

Hopeful · 10-02-2012, 02:15 PM

I think the study showed that triple positive bc behaves more like HR+/Her2- bc, with later relapses and mets to the bone instead of visceral organs. The paper also said this:

"Concordant with previous knowledge, trastuzumab increases the rates of survival independently of HR status. After stratifying by adjuvant trastuzumab use, the differences in survival by HR status persisted. It is worth noting that despite a lower rate of pathologic complete responses (pCR) among patients with HR+/HER2+ tumors across neoadjuvant trials [10, 39-45], the overall prognosis of such patients is not worse than those with HR-/HER2+ tumors. These findings also suggest that in patients with HR+/HER2+ tumors, lack of pCR will, potentially, have less prognostic value than among patients with HR-/HER2+ tumors [46]."

Hopeful

10-02-2012, 02:15 PM	#2
Hopeful Senior Member Join Date: Aug 2006 Posts: 3,380	Re: 3000 person study-- her2+ early breast cancer divided into two groups by HR statu I think the study showed that triple positive bc behaves more like HR+/Her2- bc, with later relapses and mets to the bone instead of visceral organs. The paper also said this: "Concordant with previous knowledge, trastuzumab increases the rates of survival independently of HR status. After stratifying by adjuvant trastuzumab use, the differences in survival by HR status persisted. It is worth noting that despite a lower rate of pathologic complete responses (pCR) among patients with HR+/HER2+ tumors across neoadjuvant trials [10, 39-45], the overall prognosis of such patients is not worse than those with HR-/HER2+ tumors. These findings also suggest that in patients with HR+/HER2+ tumors, lack of pCR will, potentially, have less prognostic value than among patients with HR-/HER2+ tumors [46]." Hopeful